Companies › InnoPharmax
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| D07001-Softgel Capsules Gemcitabine, a nucleoside analog | RRM1, RRM2 | Phase 3 | Biliary Tract Cancer (BTC); Biliary Tract Cancer | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05065957 | D07001-Softgel Capsules | Phase 2 | Biliary Tract Cancer | Oncology | Jul 2025 |
| NCT06622057 | D07001-Softgel Capsules | Phase 3 | Biliary Tract Cancer (BTC) | Oncology | Dec 2028 |
Theravia Beijing Immunochina Medical Science & Technology Jiangsu Healthy Life Innovation Medical Technology Jiangsu Hansoh Pharmaceutical
Theravia Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Sumitomo Pharma Switzerland
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.